DURECT Corp

NASDAQ:DRRXUnited States

DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Contact Information

Headquarters

10240 Bubb RoadCUPERTINO, CA, United States 95014

Phone

408-777-1417

Fax

408-777-3577

Executives

Independent Chairman of the Board

Gail Maderis

President, Chief Executive Officer, Director

James Brown

Chief Financial Officer, Company Secretary

Timothy Papp

Chief Medical Officer

Norman Sussman

Independent Director

Mohammad Azab